NTRK1 and colorectal cancer: Regorafenib is a multi-kinase inhibitor that targets PDGFR-β, VEGFR1-3, FGFR, and oncogenic receptor tyrosine kinases (RET, KIT, and RAF) and is indicated for the treatment of colorectal cancer and gastrointestinal tumors [169,170].